At our recent Essjay & Sagittal 2026 offsite, Dr Michael Forstner Damebois focuses on the implications of the recent CIOMS XII Working Group guidance on structured benefit-risk assessments for clinical development and post-marketing activities around benefit-risk optimisation of medicines. Michael also discusses some potential future applications of BR management ensuing from the considerations in CIOMS XII.